TY - JOUR
T1 - Guest edited collection serological study of SARS-CoV-2 antibodies in japanese cats using protein-A/G-based ELISA
AU - Imanishi, Ichiro
AU - Asahina, Ryota
AU - Hayashi, Shunji
AU - Uchiyama, Jumpei
AU - Hisasue, Masaharu
AU - Yamasaki, Masahiro
AU - Murata, Yoshiteru
AU - Morikawa, Shigeru
AU - Mizutani, Tetsuya
AU - Sakaguchi, Masahiro
N1 - Funding Information:
This study was funded by JSPS KAKENHI Grant No. 21K14976 (Imanishi), Tokyo Metropolitan Government Grant funded the survey (No. 2020-Univ-4; Mizutani), Azabu University Research Funds (Uchiyama and Sakaguchi), and Parents’ Association Grant of School of Medicine, Kitasato University (Imanishi).
Funding Information:
We acknowledge the bioresource banking project of Azabu University funded by MEXT Private University Research Branding Project, 2016–2020, in which the samples were collected by Tsujimoto. We thank the Chiba Veterinary Medical Association and Shizuoka Veterinary Medical Association, the University of Tokyo (Oono, Tomiyasu, and Momoi), and 101 veterinary clnics, especially Suto, Sugiyama, Chimura, Akiyoshi, Yugeta, Hattori, Fujita, Watanabe, and Hirabayashi, for sample collection in this study. We also thank Online English (Granton, Australia) for the English language revision of this manuscript.
Funding Information:
We acknowledge the bioresource banking project of Azabu University funded by MEXT Private University Research Branding Project, 2016–2020, in which the samples were collected by Tsujimoto. We thank the Chiba Veterinary Medical Association and Shizuoka Veterinary Medical Association, the University of Tokyo (Oono, Tomiyasu, and Momoi), and 101 veterinary clnics, especially Suto, Sugiyama, Chimura, Akiyoshi, Yugeta, Hattori, Fujita, Watanabe, and Hirabayashi, for sample collection in this study. We also thank Online English (Granton, Australia) for the English language revision of this manuscript.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Background: Little is known about the epidemic status of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cats in Japan due to insufficiently reliable seroepidemiological analysis methods that are easy to use in cats. Results: We developed a protein-A/G-based enzyme-linked immunosorbent assay (ELISA) to detect antibodies against SARS-CoV-2 in cats. The assay was standardized using positive rabbit antibodies against SARS-CoV-2. The ELISA results were consistent with those of a conventional anti-feline-immunoglobulin-G (IgG)-based ELISA. To test the protein-A/G-based ELISA, we collected blood samples from 1,969 cats that had been taken to veterinary clinics in Japan from June to July 2020 and determined the presence of anti-SARS-CoV-2 antibodies. Nine cats were found to have SARS-CoV-2 S1-specific IgG, of which 4 had recombinant receptor-binding domain-specific IgG. Of those 9 samples, one showed neutralizing activity. Based on these findings, we estimated that the prevalence of SARS-CoV-2 neutralizing antibodies in cats in Japan was 0.05% (1/1,969 samples). This prevalence was consistent with the prevalence of neutralizing antibodies against SARS-CoV-2 in humans in Japan according to research conducted at that time. Conclusions: Protein-A/G-based ELISA has the potential to be a standardized method for measuring anti-SARS-CoV-2 antibodies in cats. The infection status of SARS-CoV-2 in cats in Japan might be linked to that in humans.
AB - Background: Little is known about the epidemic status of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cats in Japan due to insufficiently reliable seroepidemiological analysis methods that are easy to use in cats. Results: We developed a protein-A/G-based enzyme-linked immunosorbent assay (ELISA) to detect antibodies against SARS-CoV-2 in cats. The assay was standardized using positive rabbit antibodies against SARS-CoV-2. The ELISA results were consistent with those of a conventional anti-feline-immunoglobulin-G (IgG)-based ELISA. To test the protein-A/G-based ELISA, we collected blood samples from 1,969 cats that had been taken to veterinary clinics in Japan from June to July 2020 and determined the presence of anti-SARS-CoV-2 antibodies. Nine cats were found to have SARS-CoV-2 S1-specific IgG, of which 4 had recombinant receptor-binding domain-specific IgG. Of those 9 samples, one showed neutralizing activity. Based on these findings, we estimated that the prevalence of SARS-CoV-2 neutralizing antibodies in cats in Japan was 0.05% (1/1,969 samples). This prevalence was consistent with the prevalence of neutralizing antibodies against SARS-CoV-2 in humans in Japan according to research conducted at that time. Conclusions: Protein-A/G-based ELISA has the potential to be a standardized method for measuring anti-SARS-CoV-2 antibodies in cats. The infection status of SARS-CoV-2 in cats in Japan might be linked to that in humans.
KW - Cats
KW - Health risk behaviours
KW - SARS-CoV-2
KW - Seroepidemiological studies
UR - http://www.scopus.com/inward/record.url?scp=85144334111&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144334111&partnerID=8YFLogxK
U2 - 10.1186/s12917-022-03527-7
DO - 10.1186/s12917-022-03527-7
M3 - Article
C2 - 36539820
AN - SCOPUS:85144334111
SN - 1746-6148
VL - 18
JO - BMC Veterinary Research
JF - BMC Veterinary Research
IS - 1
M1 - 443
ER -
